These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 35227613)

  • 1. Response to Letter to Editor re: "Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms".
    Lee H; Nakamoto R; Moore SE; Pantel AR; Eads JR; Aparici CM; Pryma DA
    Acad Radiol; 2022 Sep; 29(9):1453. PubMed ID: 35227613
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to Editor Re: "Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms" (https://doi.org/10.1016/j.acra.2021.10.004).
    Chan DL; Roach PJ; Bailey DL
    Acad Radiol; 2022 Sep; 29(9):1452. PubMed ID: 35219586
    [No Abstract]   [Full Text] [Related]  

  • 3. The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact.
    Hayes AR; Furtado O'Mahony L; Quigley AM; Gnanasegaran G; Caplin ME; Navalkissoor S; Toumpanakis C
    Clin Nucl Med; 2022 Jan; 47(1):26-35. PubMed ID: 34874347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Quantification of
    Lee H; Nakamoto R; Moore SE; Pantel AR; Eads JR; Aparici CM; Pryma DA
    Acad Radiol; 2022 Sep; 29(9):1308-1316. PubMed ID: 34836776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
    Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT Findings in a Patient With Primary Renal Well-Differentiated Neuroendocrine Tumor.
    Şahin R; Baykal Koca S; Yücetaş U; Çermik TF; Ergül N
    Clin Nucl Med; 2022 Jul; 47(7):e503-e505. PubMed ID: 35384913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
    Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT "Superscan" in Metastatic Pancreatic Neuroendocrine Tumor.
    Chan M; Schembri GP
    Clin Nucl Med; 2017 Feb; 42(2):108-109. PubMed ID: 27997429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated PET/MRI With 68Ga-DOTATATE and 18F-FDG in Pheochromocytomas and Paragangliomas: An Initial Study.
    Xu S; Pan Y; Zhou J; Ju H; Zhang Y
    Clin Nucl Med; 2022 Apr; 47(4):299-304. PubMed ID: 35143455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging Characteristics of Coexisting Primary Pulmonary Carcinoid Tumor and Multiple Myeloma on 18F-FDG and 68Ga-DOTATATE PET/CT.
    Lu Y
    Clin Nucl Med; 2019 Nov; 44(11):914-915. PubMed ID: 31306189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.
    Acar E; Kaya GÇ
    Clin Nucl Med; 2019 Jan; 44(1):53-54. PubMed ID: 30325820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
    Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
    J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case of Brown Tumor on 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT.
    Yao X; Ou X
    Clin Nucl Med; 2022 Jan; 47(1):88-89. PubMed ID: 34874352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 68Ga-DOTATATE PET/CT in Primary Pulmonary Lymphoepithelioma-Like Carcinoma.
    Shang Q; Pang Y; Meng T; Hao B; Chen H
    Clin Nucl Med; 2022 Feb; 47(2):187-189. PubMed ID: 34319951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Prognostic Value of PET/CT Imaging with Combination of
    Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M
    Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.
    Hindié E
    Theranostics; 2017; 7(5):1159-1163. PubMed ID: 28435455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.